Sponsored Links
Lymphoma Information Network » Lymphoma Info » Follicular Lymphoma

Follicular Lymphoma

spleen
Follicular lymphoma in spleen,
AFIP Atlas of Tumor Pathology

Follicular Lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects B-Cell Lymphocytes. Like most lymphomas, this cancer usually begins in the lymph nodes; it can spread into the blood and bone marrow, as well as the internal organs, in more advanced stages of the disease. The liver and spleen may also be affected.

Follicular lymphoma accounts for a high percentage of B-Cell Lymphomas. Approximately 20-30% of cases of NHL are diagnosed as Follicular Lymphoma. Most of these diagnoses occur in adults over the age of 60, with an equal occurrence in males and females.

Diagnosis and Staging

Most patients with Follicular Lymphoma will have little to no symptoms until the later stages of the disease because it is indolent. Symptoms include painless, swollen lymph nodes in the neck, armpit, or groin, fever, fatigue, night sweats, and unexplained weight loss.

If the doctor suspects cancer, he will conduct a biopsy on an affected lymph node. A chest X-ray, CT or PET scan, or other diagnostic tests may also be ordered to help stage the disease.

Stage I
Marked by the involvement of only one group of lymph nodes or one section of organ tissue.
Stage II
The disease has spread to two lymph groups on the same side of the diaphragm, or to a lymph group and nearby organ.
Stage III
The disease includes lymph nodes on both sides of the diaphragm.
Stage IV
The disease involves multiple internal organs, including the liver, bone marrow, and blood.

Follicular lymphomas are also divided into three grades, based on the ratio of large to small B-cells affected.

Grade 1
Cancer is made up of all small cells.
Grade 2
Cancer is a mixture of large and small cells.
Grade 3
Cancer affects mostly large cells; generally more aggressive.

Even though most patients are diagnosed in later stages of the disease, prognosis is still good. There is a 70% chance of survival at the ten-year mark.

Treatment

Treatments vary based on the stage of the disease. Luckily, follicular lymphomas are very sensitive to both radiation and chemotherapy, so treatment is highly effective. Methods include:

  • Radiation treatment, especially in earlier stages of the disease (Stage I and II).
  • Chemotherapy regimens, like the CHOP protocol (cyclophosphamide, doxorubicin, vincristine, and prednisone).
  • Monoclonal antibodies such as Rituximab, Bexxar, or Zevalin.
  • Combined regimens, especially the R-VCP protocol. This uses the monoclonal antibody rituximab, along with chemotherapy agents cyclophosphamide and vincristine. Prednisone, a steroid, is used to help prevent internal swelling and keep organs healthy while on this regimen.
  • Stem Cell Transplant is used in patients with relapsed lymphoma.
  • The wait and watch method is used for patients who are diagnosed but aren't presenting symptoms. This method has the same survival rate as patients who are treated before symptoms present. Once a patient shows common symptoms of the disease, treatment is administered.
  • Patients who are looking for more advanced treatment or who have lymphoma that does not respond to standard treatment may want to consider a clinical study. Click here to find clinical trials in your area.
  • These are some of many treatment options for Lymphoma. If you are looking for some assistance with treatment options, there is a free tool available to help you understand your treatment options and possible side effects. Click here to sign up for free.

Cited for Reference

Indolent Follicular Lymphoma fact sheet from the Lymphoma Research Foundation

Sponsored Links

Cancer Support Groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Dive Deeper

Related Articles

disclaimer

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.

Featured Treatment
searching for treatment

Featured Treatment: Zevalin®

Zevalin® (Ibritumomab tiuxetan) is a form of radioimmunotherapy (a radiolabeled monoclonal antibody) for treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL). "Refractory" refers to a disease that does not respond to treatment.

Zevalin is the first radioummunotherapy treatment to be FDA-approved as a first-line therapy for lymphoma. Read more...

Sponsored Links
User login
Cancer Support Groups

Cancer Support Groups

support groups

SupportGroups.com aims to build awareness and provide support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. If you are a friend or parent of a person that has been diagnosed with Lymphoma, or you have been diagnosed with Lymphoma, you are not alone. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Poll
What is most important to you in an Online Support Group?:
Latest Blog Entries
Did You Know?
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Incidence rates for Hodgkin’s disease have declined about 60%. Better means of diagnosis has also increased the number as doctors better understand cancer of lymphocytes verses other diseases.